Device Trials Should Better Reflect Real World, Says CDRH’s Kessler
This article was originally published in The Gray Sheet
Executive Summary
A high-level CDRH staffer delivered a stern message last week to device companies: they need to conduct clinical trials more applicable to the real world
You may also be interested in...
Larger Clinical Studies Required To Assess Device Risk/Benefit – Duke’s Califf
A rethinking of the U.S. clinical trials system is needed to truly understand the risks and benefits of current and future devices and drugs, Duke Clinical Research Institute Director Robert Califf, MD, asserted at the FDA Science Forum April 28
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.